All In Biotech

Drug Trial Radar · NCT04550104

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

A Platform Study of DNA Damage Response Inhibitors in Combination With Conventional Radiotherapy in Non Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Mar 17, 2021

Primary completion

Mar 2026

Study completion Mar 2028

Sponsor

Lead sponsor
University of LeedsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Manchester; Newcastle University; University of Oxford; The Leeds Teaching Hospitals NHS Trust; Beatson West of Scotland Cancer Centre; University of Glasgow; Velindre NHS Trust; University College London Hospitals; Queen's University, Belfast; University of Sheffield
First posted
Sep 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CONCORDE is a multi-institution, multi-arm, Phase IB study that will determine the recommended phase II dose (RP2D) and safety profiles of different DNA damage repair inhibitors (DDRis) when given in an open label fashion in combination with fixed dose curative intent radiotherapy (RT) in patients with stage IIB/IIIA/IIIB NSCLC, followed by up to 12 months of consolidation durvalumab immunotherapy in selected study arms. The RP2D will be evaluated by incorporating the number of observed dose limiting toxicities (DLTs) into a time to event continuous reassessment method (TiTE- CRM) model within each of the experimental arms. TiTE-CRM is used here to take into account longer-term toxicities up to 13.5 months post start of radiotherapy and use these to inform dose escalation decision making.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • RadiotherapyRadiation

    Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.

  • Olaparib Oral Tablet [Lynparza]Drug

    Oral tablet

  • AZD1390Drug

    Oral tablet

  • CeralasertibDrug

    Oral Tablet

  • AZD5305Drug

    Oral Tablet

  • DurvalumabDrug

    1500mg iv infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting ToxicitiesTime frame: 13.5 months after start of radiotherapy

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Belfast City Hospital

    Belfast, United Kingdom · Recruiting

  • Birmingham Heartlands Hospital

    Birmingham, United Kingdom · Recruiting

  • Addenbrooke's Hospital

    Cambridge, United Kingdom · Recruiting

  • Velindre Cancer Centre

    Cardiff, United Kingdom · Recruiting

  • The Royal Marsden Hospital Chelsea

    Chelsea, United Kingdom · Recruiting

  • Western General Hospital

    Edinburgh, United Kingdom · Recruiting

  • St James's University Hospital

    Leeds, United Kingdom · Recruiting

  • The Clatterbridge Cancer Centre

    Liverpool, United Kingdom · Recruiting

  • St Bartholomew's Hospitals

    London, United Kingdom · Recruiting

  • University College Hospital London

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust

    Newcastle upon Tyne, United Kingdom · Recruiting

  • Weston Park Hospital

    Sheffield, United Kingdom · Recruiting

  • The Royal Marsden Sutton

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.